Neo-Giluritmal
Producer: Solvay Pharmaceuticals, (Solvey Pharmasyyutikalz) GmbH Germany
Code of automatic telephone exchange: C01BA08
Release form: Firm dosage forms. Tablets.
General characteristics. Structure:
Active ingredient: praymalina of a bitartrate of 20 mg.
Pharmacological properties:
Pharmacological action - antiarrhytmic.
Indications to use:
Tachycardic supraventricular, AV and ventrikulyarny arrhythmias.
Route of administration and doses:
Inside, after food with a small amount of liquid, in an initial dose 1 tablet 3–4 times a day within 2–3 days. At a maintenance therapy the initial dose is gradually reduced to 1/2 tablets by 2–4 times a day. In out-patient conditions it is not necessary to exceed a daily dose in 100 mg, in stationary conditions — 120 mg.
Features of use:
There are no data.
Side effects:
Nausea, feeling of heat, headache, lack of appetite, lock, intra hepatic cholestasia (the increased temperature, an itch, yellowing of a sclera of eyes, coloring of urine in brown color, a light chair), a visual disturbance, a leukopenia, thrombocytopenia, pro-arhythmic effects.
Interaction with other medicines:
Cardiac glycosides or other antiarrhytmic drugs can strengthen bradycardia or negative dromotropic effect.
Contraindications:
Disturbances of AV and intraventricular conductivity, Adams's attacks — Stokes, disturbance of a cordial rhythm against the background of bradycardia, pregnancy.
Overdose:
There are no data.
Storage conditions:
To store in the place, unavailable to children.
Issue conditions:
According to the recipe
Packaging:
1 tablet contains a praymalin of a bitartrate of 20 mg, in packaging of 50 pieces.